Jiangsu Hengrui says NMPA approves two new Hetrombopag olamine indications
Jiangsu Hengrui Pharmaceuticals Co Ltd said China’s NMPA has approved two new indications for its Hetrombopag olamine tablets. The company is listed on the SSE under 600276.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.